✦ LIBER ✦

Clinical randomized comparative trial of DICE regimen and CHOP regimen in treating intermediate and high grade non-Hodgkin’s lymphoma

✍ Scribed by Wenwu Wang; Xuenong OuYang; Zhangshu Cheng; Yonghai Peng; Fangwei Xie; Zongyang Yu

Book ID: 106314747
Publisher: Springer
Year: 2008
Tongue: English
Weight: 169 KB
Volume: 7
Category: Article
ISSN: 1610-1979
DOI: 10.1007/s10330-007-0164-7

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Analysis of efficacy of DICE (dexamethas

Analysis of efficacy of DICE (dexamethasone, ifosfamide, cisplatin and etoposide) regimen on recurrent and refractory intermediate and high grade non-Hodgkin’s lymphoma

✍ Yang, Lei ;Song, Zhucheng ;Xu, Xiaohong ;Wei, Jinzhi ;Tan, Qinghe ;Cong, Zhirong 📂 Article 📅 2009 🏛 Springer-Verlag ⚖ 312 KB

Chop treatment in eighty cases of interm

Chop treatment in eighty cases of intermediate and high grade non-Hodgkin's lymphomas

✍ Dallavalle, G.; Tedeschi, L.; Romanelli, A.; Labianca, R.; Luporini, G. 📂 Article 📅 1993 🏛 Elsevier Science 🌐 English ⚖ 153 KB

Alternating chemotherapy regimen (P-VABE

Alternating chemotherapy regimen (P-VABEC) for intermediate and high-grade non-Hodgkin's lymphoma of the middle aged and elderly

✍ Dr. F. Caracciolo; M. Petrini; E. Capochiani; F. Papineschi; G. Carulli; B. Gras 📂 Article 📅 1994 🏛 John Wiley and Sons 🌐 English ⚖ 463 KB 👁 1 views

An intensive third generation regimen (P-VABEC) including adriamycin, etoposide, cyclophosphamide. vincristine, bleomycin and prednisolone was administered to 43 unselected elderly patients with intermediate or high-grade non-Hodgkin's lymphomas (NHL). The median age was 67, 40 per cent were Ann Arb

Long-term Results of a Multicenter Rando

Long-term Results of a Multicenter Randomized, Comparative Trial of Modified CHOP versus THP-COP versus THP-COPE Regimens in Elderly Patients with Non-Hodgkin’s Lymphoma

✍ Mayumi Mori; Kiyoshi Kitamura; Michihiko Masuda; Tomomitsu Hotta; Tamotsu Miyaza 📂 Article 📅 2005 🏛 Carden Jennings Publishing 🌐 English ⚖ 161 KB

Phase II trial of bisantrene in patients

Phase II trial of bisantrene in patients with intermediate and high grade diffuse non-Hodgkin's lymphomas

✍ Thomas P. Miller; Stephen E. Jones; David S. Alberts; Cindy Mackel 📂 Article 📅 1984 🏛 Springer US 🌐 English ⚖ 239 KB

Sixteen heavily pretreated patients with advanced intermediate and high-grade diffuse non-Hodgkin's lymphoma (NHL) were treated with 260 mg/M2 of bisantrene every three weeks. Thirty infusions of bisantrene were given without evidence of objective response. Pain in the infused arm, with or without s

Adjubant chop chemotherapy following rad

Adjubant chop chemotherapy following radiotherapy in stage I low and intermediate grade non-hodgkin's lymphoma: Results of a prospective randomized study

✍ George Varsos; Joachlm Yahalom; Zvi Fuks; Jane Myers; Bayard Clarkson; David Str 📂 Article 📅 1991 🏛 Elsevier Science 🌐 English ⚖ 114 KB